Abemaciclib for the treatment of HR+/HER2- breast cancer

Exman, P; Tolaney, SM

Tolaney, SM (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,Yawkey 1257, Boston, MA 02215 USA.

EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2018; 3 (3): 151

Abstract

Introduction: More than 70% of patients with advanced breast cancer have hormone receptor (HR)-positive disease and almost all patients will develop r......

Full Text Link